

Appendix Table F32. Clinical outcomes after topical estrogen therapy compared to no treatment (individual RCTs)

Reference sample	Active	Definition of outcome	Randomized active/control	Active events/rate	Control events/rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1,000 treated (95% CI)
Waetjen, 2005 ³⁹⁹ 417/0	14 mg of transdermal E2 per day for 4 months	Worsened urge incontinence: the number of incontinence episodes per week increased by 2 or more.	208/209	5/2	21/10	0.24 (0.09; 0.62)	-0.08 (-0.12; -0.03)	-13 (-33; -8)	-76 (-122; -31)
Waetjen, 2005 ³⁹⁹ 417/0	for 2 years	Worsened urge incontinence: the number of incontinence episodes per week increased by 2 or more.	208/209	27/13	38/18	0.71 (0.45; 1.12)	-0.05 (-0.12; 0.02)		
Waetjen, 2005 ³⁹⁹ 417/0	for 2 years	Worsened incontinence	208/209	35/17	35/17	1.00 (0.66; 1.54)	0.00 (-0.07; 0.07)		
Waetjen, 2005 ³⁹⁹ 417/0	for 2 years	Worsened stress incontinence	208/209	20/10	19/9	1.06 (0.58; 1.92)	0.01 (-0.05; 0.06)		
Waetjen, 2005 ³⁹⁹ 417/0	for 4 months	Unchanged stress incontinence	208/209	136/66	124/59	1.10 (0.95; 1.28)	0.06 (-0.03; 0.15)		
Waetjen, 2005 ³⁹⁹ 417/0	for 4 months	Unchanged urge incontinence	208/209	178/86	162/77	1.10 (1.01; 1.21)	0.08 (0.01; 0.15)	12 (6; 152)	81 (7; 155)
Waetjen, 2005 ³⁹⁹ 417/0	for 4 months	Unchanged incontinence	208/209	106/51	95/46	1.12 (0.92; 1.37)	0.06 (-0.04; 0.15)		
Waetjen, 2005 ³⁹⁹ 417/0	for 2 years	Unchanged urge incontinence	208/209	154/74	136/65	1.14 (1.00; 1.29)	0.09 (0.00; 0.18)	11 (6; 568)	90 (2; 178)
Waetjen, 2005 ³⁹⁹ 417/0	for 2 years	Unchanged stress incontinence	208/209	151/73	129/62	1.18 (1.03; 1.35)	0.11 (0.02; 0.20)	9 (5; 52)	109 (19; 198)

Appendix Table F32. Clinical outcomes after topical estrogen therapy compared to no treatment (individual RCTs) (continued)

Reference sample	Active	Definition of outcome	Randomized active/control	Active events/rate	Control events/rate	Relative risk (95% CI)	Absolute risk differences (95% CI)	Number needed to treat (95% CI)	Attributable events/1,000 treated (95% CI)
Waetjen, 2005 ³⁹⁹ 417/0	for 2 years	Unchanged incontinence	208/209	116/56	94/45	1.24 (1.02; 1.50)	0.11 (0.01; 0.20)	9 (5; 80)	108 (13; 203)
Waetjen, 2005 ³⁹⁹ 417/0	for 4 months	Worsened incontinence	208/209	50/24	40/19	1.26 (0.87; 1.82)	0.05 (-0.03; 0.13)		
Waetjen, 2005 ³⁹⁹ 417/0	for 4 months	Worsened stress incontinence	208/209	42/20	28/14	1.51 (0.97; 2.34)	0.07 (0.00; 0.14)		
Waetjen, 2005 ³⁹⁹ 417/0	for 2 years	New developed incontinence at 2 years	208/209	81/39	77/37	1.06 (0.83; 1.35)	0.02 (-0.07; 0.11)		
Dessole, 2004 ²⁷² 88/0	Intravaginal estriol ovules: 1 ovule (1 mg) once daily for 2 weeks and then 2 ovules once weekly for 6 months.	Subjective complaints of stress urinary incontinence.	44/44	14/32	37/84	0.38 (0.24; 0.59)	-0.52 (-0.70; -0.35)	-2 (-3; -1)	-523 (-698; -348)
Holtedah, 1998 ³⁰⁸ 80/0	Local estrogen in tablets or jelly	Worse incontinence: self reported worsening of severity or impact	36/44	4/11	13/30	0.38 (0.13; 1.05)	-0.18 (-0.35; -0.01)	-5 (-67; -3)	-184 (-354; -15)
Holtedah, 1998 ³⁰⁸ 80/0	Local estrogen in tablets or jelly	Unchanged incontinence: no changes in frequency, amount, or wet episodes	36/44	10/28	27/61	0.45 (0.25; 0.81)	-0.34 (-0.54; -0.13)	-3 (-8; -2)	-336 (-541; -131)